成人乙型肝炎肝移植术后受者乙型肝炎疫苗主动免疫应答率与接种前CD4水平的相关性分析

王旭; 许姗姗; 荣义辉; 蔡焕静; 王贵强

doi:10.3969/j.issn.1001-5256.2021.08.012

成人乙型肝炎肝移植术后受者乙型肝炎疫苗主动免疫应答率与接种前CD4水平的相关性分析

DOI: 10.3969/j.issn.1001-5256.2021.08.012

北京大学国际医院感染肝病部，北京 102206

利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。

作者贡献声明：王旭负责课题设计，数据整理，资料分析，撰写论文；许姗姗、荣义辉、蔡焕静参与收集数据，实施具体操作；王贵强负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
王贵强，john131212@sina.com

中图分类号: R512.62;R617
计量
- 文章访问数: 535
- HTML全文浏览量: 161
- PDF下载量: 169
- 被引次数: 0
出版历程
- 收稿日期: 2021-01-14
- 录用日期: 2021-02-25
- 出版日期: 2021-08-20

Rate of active immune response to hepatitis B vaccine in adult hepatitis B recipients after liver transplantation and its correlation with CD4 level before vaccination

Department of Infection and Liver Diseases, Peking University International Hospital, Beijing 102206, China

摘要

摘要: 目的探究影响成人乙型肝炎肝移植术后受者乙型肝炎疫苗主动免疫应答率的主要临床影响因素。方法分析2019年5月—2020年11月北京大学国际医院15例乙型肝炎肝移植术后受者接种乙型肝炎疫苗的临床随诊资料，均为肝移植术后至少3年、接种前CD4水平300~800 cells/u的患者。每次予40 μg重组乙型肝炎疫苗(酿酒酵母)，接种频次按0、1、6、8个月间隔。4剂接种结束后抗-HBs≥100 mIU/L，并持续12周不衰减视为应答成功。应用Pearson相关性分析、Kendall相关性分析对接种前CD4水平及疫苗应答率的相关性进行分析；应用线性回归分析评价接种前CD4水平是否可预测疫苗主动免疫后抗-HBs水平；并应用logistic回归分析评价接种前CD4水平是否可预测疫苗能否应答。结果监测12周时，15例患者中6例应答，其中1例抗-HBs＞1000 mIU/L，5例抗-HBs≥100 mIU/L，继续监测至16周抗体滴度仍不衰减，乙型肝炎疫苗接种应答率为40%。6例应答者接种前CD4水平均≥592 cells/u，9例未应答者接种前CD4水平均≤500 cells/u。接种前CD4水平与乙型肝炎疫苗应答率呈强相关(Pearson相关性分析r=0.767，P=0.001；Kendall相关性分析r=0.717，P=0.001)。结论接种前的CD4水平是影响肝移植术后乙型肝炎疫苗应答率的关键因素。
- 乙型肝炎 /
- 肝移植 /
- 乙型肝炎疫苗 /
- 抗原, CD4
Abstract: Objective To investigate the main clinical influencing factors for the rate of active immune response to hepatitis B vaccine in adult hepatitis B recipients after liver transplantation. Methods Analysis was performed for the clinical follow-up data of 15 hepatitis B recipients after liver transplantation who received hepatitis B vaccine in Peking University International Hospital from May 2019 to November 2020, and all patients received liver transplantation at least 3 years before and had a CD4 level of 300-800 cells/u before vaccination. Each dose of vaccination was 40 μg recombinant hepatitis B vaccine (Saccharomyces cerevisiae), with a total of 4 injections at 0, 1, 6, and 8 months. Anti-HBs ≥100 mIU/L after four injections which lasted for 12 weeks without attenuation was considered successful response. Pearson correlation analysis and Kendall correlation analysis were used to investigate the correlation between CD4 level before vaccination and vaccine response rate; a linear regression analysis was used to investigate whether CD4 level before vaccination could predict the titer of anti-HBs after active vaccine immunization; a logistic regression analysis was used to investigate whether CD4 level before vaccination could predict vaccine response. Results Of all patients at week 12 of monitoring, 6 patients had response, among whom 1 had an anti-HBs level of > 1000 mIU/L and 5 had an anti-HBs level of ≥100 mIU/L, and the antibody titer did not attenuate till week 16; the response rate of hepatitis B vaccine was 40%. The 6 patients with response had a mean CD4 level of ≥592 cells/u before vaccination, while the 9 patients without response had a mean CD4 level of ≤500 cells/u before vaccination. CD4 level before vaccination was strongly correlated with the response rate of hepatitis B vaccine (Pearson correlation analysis: r=0.767, P=0.001; Kendall correlation: r=0.717, P=0.001). Conclusion CD4 level before vaccination is a key clinical factor affecting the response rate of hepatitis B vaccine after liver transplantation.
- Hepatitis B /
- Liver Transplantation /
- Hepatitis B Vaccines /
- Antigens, CD4

HTML全文

表 1 15例患者接种前CD4水平及完成乙型肝炎疫苗接种后抗-HBs的变化

病例	接种前CD4 (cells/u)	4剂全部接种完成后抗-HBs水平(mIU/L)
病例	接种前CD4 (cells/u)	4周	8周	12周	16周
病例1	238	22.76(乙免)
病例2	279	69.28	55.73(乙免)
病例3	306	39.18(乙免)
病例4	324	55.68	67.90	58.12(乙免)
病例5	362	61.09	54.61(乙免)
病例6	378	39.65(乙免)
病例7	418	59.66	40.66(乙免)
病例8	448	78.70	65.01	30.84(乙免)
病例9	500	44.08(乙免)
病例10	592	133.05	235.43	291.50	350.01
病例11	598	170.07	162.69	180.17	167.47
病例12	663	109.37	96.23	114.10	128.33
病例13	670	105.11	144.23	154.95	188.18
病例14	678	220.39	367.10	210.80	236.89
病例15	803	489.47	798.01	＞1000	＞1000
注：“乙免”表示注射乙型肝炎免疫球蛋白。接种结束后，一旦抗-HBs持续低于60 mIU/L即需要接种乙型肝炎免疫球蛋白，此类患者视为无应答，且接种乙型肝炎免疫球蛋白后再次化验抗-HBs非疫苗接种后真实滴度，故不再继续监测抗-HBs。

下载: 导出CSV

参考文献(8)

[1]	GUO Y, WANG WT, LI ZQ, et al. Hepatitis B vaccination: A new strategy to prevent hepatitis B recurrence after liver transplantation for hepatitis B virus-related recipients[J]. Chin J Hepatobiliary Surg, 2015, 21(10): 668-670. DOI: 10.3760/cma.j.issn.1007-8118.2015.10.006. 郭源, 王文涛, 李自强, 等. 乙肝疫苗接种: 乙肝相关肝移植受者预防乙肝复发的新策略[J]. 中华肝胆外科杂志, 2015, 21(10): 668-670. DOI: 10.3760/cma.j.issn.1007-8118.2015.10.006.
[2]	SÁNCHEZ-FUEYO A, RIMOLA A, GRANDE L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation[J]. Hepatology, 2000, 31(2): 496-501. DOI: 10.1002/hep.510310233.
[3]	BÁRCENA R, FERNANDEZ-BRASO M, URMAN J, et al. Response to hepatitis B virus vaccine in patients transplanted for HBV-related liver disease under specific gammaglobulin prophylaxis[J]. Transplant Proc, 1999, 31(6): 2459-2460. DOI: 10.1016/s0041-1345(99)00417-0.
[4]	GARÇON N, van MECHELEN M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems[J]. Expert Rev Vaccines, 2011, 10(4): 471-486. DOI: 10.1586/erv.11.29.
[5]	VANDEPAPELIÈRE P, HORSMANS Y, MORIS P, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers[J]. Vaccine, 2008, 26(10): 1375-1386. DOI: 10.1016/j.vaccine.2007.12.038.
[6]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[7]	BIENZLE U, GVNTHER M, NEUHAUS R, et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease[J]. Hepatology, 2003, 38(4): 811-819. DOI: 10.1053/jhep.2003.50396.
[8]	DI PAOLO D, LENCI I, TRINITO MO, et al. Extended HBV vaccination in liver transplant recipients for HBV-related cirrhosis: Report of two successful cases[J]. Dig Liver Dis, 2005, 37(10): 793-798. DOI: 10.1016/j.dld.2005.01.023.